[en] We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] Abeta42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it "always/frequently") followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as "moderate". Seventy-nine percent of responders felt "very/extremely" comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P < .02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature.
Research center :
GIGA CRC (Cyclotron Research Center) In vivo Imaging-Aging & Memory - ULiège
Disciplines :
Neurology
Author, co-author :
Bochetta, M
Galluzi, S
Kehoe, P.G.
Aguera, E
Bernabei, R
Bullock, R
Ceccaldi, M
Dartigues, J.F.
de Mendonca, A
Didic, M
Erikdotter, M
Felician, O
Frolich, L
Gertz, H.J.
Hallikainen, M
Hasselbach, S.G.
Hausner, L
Heuser, I
Jessen, F
Jones, R.W.
Kurz, A
Lawlor, B
Lleo, A
Martinez-Lage, P
Mecocci, P
Mehrabian, S
Monsch, A
Nobili, F
Nordberg, A
Olde Rikkert, M
Orgogozo, J.M.
Pasquier, F
Peters, O
Salmon, Eric ; Université de Liège > Département des sciences cliniques > Neuroimagerie des troubles de la mémoire et révalid. cogn.
Dubois, B., Feldman, H.H., Jacova, C., Dekosky, S.T., Barberger-Gateau, P., Cummings, J., Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria (2007) Lancet Neurol, 6, pp. 734-746
Dubois, B., Feldman, H.H., Jacova, C., Cummings, J.L., Dekosky, S.T., Barberger-, G.P., Revising the definition of Alzheimer's disease: A new lexicon (2010) Lancet Neurol, 9, pp. 1118-1127
Sperling, R.A., Aisen, P.S., Beckett, L.A., Bennett, D.A., Craft, S., Fagan, A.M., Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease (2011) Alzheimers Dement, 7, pp. 280-292
Albert, M.S., Dekosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N.C., The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the national institeon aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease (2011) Alzheimers Dement, 7, pp. 270-279
Mckhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R., Jr., Kawas, C.H., The diagnosis of dementia due to Alzheimer's disease: Recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease (2011) Alzheimers Dement, 7, pp. 263-269
Frisoni, G.B., Hampel, H., O'Brien, J.T., Ritchie, K., Winblad, B., Revised criteria for Alzheimer's disease: What are the lessons for clinicians? (2011) Lancet Neurol, 10, pp. 598-601
Prestia, A., Caroli, A., Herholz, K., Reiman, E., Chen, K., Jagust, W.J., Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series (2013) Alzheimers Dement, 9, pp. 677-686
Prestia, A., Caroli, A., Van Der Flier, W.M., Ossenkoppele, R., VanBerckel, B., Barkhof, F., Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease (2013) Neurology, 80, pp. 1048-1056
Shaffer, J.L., Petrella, J.R., Sheldon, F.C., Choudhury, K.R., Calhoun, V.D., Coleman, R.E., Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers (2013) Radiology, 266, pp. 583-591
Choo, I.H., Ni, R., Scholl, M., Wall, A., Almkvist, O., Nordberg, A., Combination of (18)F-FDG-PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients (2013) J Alzheimers Dis, 33, pp. 929-939
Clark, C.M., Pontecorvo, M.J., Beach, T.G., Bedell, B.J., Coleman, R.E., Doraiswamy, P.M., Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: A prospective cohort study (2012) Lancet Neurol, 11, pp. 669-678
Scheltens, P., Leys, D., Barkhof, F., Huglo, D., Weinstein, H.C., Vermersch, P., Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: Diagnostic value and neuropsychological correlates (1992) J Neurol Neurosurg Psychiatry, 55, pp. 967-972
Fazekas, F., Chawluk, J.B., Alavi, A., Hurtig, H.I., Zimmerman, R.A., MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging (1987) AJR Am J Roentgenol, 149, pp. 351-356
Wahlund, L.O., Barkhof, F., Fazekas, F., Bronge, L., Augustin, M., Sjogren, M., A new rating scale for age-related white matter changes applicable to MRI and CT (2001) Stroke, 32, pp. 1318-1322
Pasquier, F., Leys, D., Weerts, J.G., Mounier-Vehier, F., Barkhof, F., Scheltens, P., Inter- And intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts (1996) EurNeurol, 36, pp. 268-272
Hort, J., O'Brien, J.T., Gainotti, G., Pirttila, T., Popescu, B.O., Rektorova, I., EFNS guidelines for the diagnosis and management of Alzheimer's disease (2010) Eur J Neurol, 17, pp. 1236-1248
Knopman, D.S., Dekosky, S.T., Cummings, J.L., Chui, H., Corey-Bloom, J., Relkin, N., Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the quality standards subcommittee of the American academy of neurology (2001) Neurology, 56, pp. 1143-1153
Jack, C.R., Jr., Knopman, D.S., Jagust, W.J., Shaw, L.M., Aisen, P.S., Weiner, M.W., Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade (2010) Lancet Neurol, 9, pp. 119-128
Bastos-Leite, A.J., Van Der Flier, W.M., Van Straaten, E.C., Staekenborg, S.S., Scheltens, P., Barkhof, F., The contribution of medial temporal lobe atrophy and vascular pathology to cognitive impairment in vascular dementia (2007) Stroke, 38, pp. 3182-3185
Laakso, M.P., Partanen, K., Riekkinen, P., Lehtovirta, M., Helkala, E.L., Hallikainen, M., Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: An MRI study (1996) Neurology, 46, pp. 678-681
Chan, D., Fox, N.C., Scahill, R.I., Crum, W.R., Whitwell, J.L., Leschziner, G., Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease (2001) Ann Neurol, 49, pp. 433-442
Van De Pol, L.A., Hensel, A., Van Der Flier, W.M., Visser, P.J., Pijnenburg, Y.A., Barkhof, F., Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's disease (2006) J Neurol Neurosurg Psychiatry, 77, pp. 439-442
Slats, D., Spies, P.E., Sjogren, M.J., Visser, P.J., Verbeek, M.M., Olderikkert, M.G., CSF biomarker utilisation and ethical considerations of biomarker assisted diagnosis and research in dementia: Perspectives from within the European Alzheimer's Disease Consortium (2010) J Neurol Neurosurg Psychiatry, 81, pp. 124-125. , EADC
Lista, S., Garaci, F.G., Ewers, M., Teipel, S., Zetterberg, H., Blennow, K., CSF Abeta1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease (2014) Alzheimers Dement, 10, pp. 381-392
Mattsson, N., Zetterberg, H., Hansson, O., Andreasen, N., Parnetti, L., Jonsson, M., CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment (2009) JAMA, 302, pp. 385-393
Mitchell, A.J., Monge-Argiles, J.A., Sanchez-Paya, J., Do CSF biomarkers help clinicians predict the progression of mild cognitive impairment to dementia? (2010) PractNeurol, 10, pp. 202-207
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., Minthon, L., Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study (2006) Lancet Neurol, 5, pp. 228-234
Lehman, V.T., Carter, R.E., Claassen, D.O., Murphy, R.C., Lowe, V., Petersen, R.C., Visual assessment versus quantitative threedimensional stereotactic surface projection fluorodeoxyglucose positron emission tomography for detection of mild cognitive impairment and Alzheimer disease (2012) Clin Nucl Med, 37, pp. 721-726
Burdette, J.H., Minoshima, S., Vander, B.T., Tran, D.D., Kuhl, D.E., Alzheimer disease: Improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections (1996) Radiology, 198, pp. 837-843
Ng, S., Villemagne, V.L., Berlangieri, S., Lee, S.T., Cherk, M., Gong, S.J., Visual assessment versus quantitative assessment of 11C-PIB PETand 18F-FDG-PET for detection of Alzheimer's disease (2007) J Nucl Med, 48, pp. 547-552
CHMP, (2013) Amyvidflorbetapir, , Committee for Medicinal Products for Human Use.(18F). EMA/696925/2012
(2012) FDA Approves Imaging Drug Amyvid, , http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm299678.htm, Food and Drug Administration. Available at:, Accessed July 22, 2014
(2013) FDA Approves Second Brain Imaging Drug to Help Evaluate Patients for Alzheimer's Disease, Dementia, , http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm372261.htm, Food and Drug Administration. Accessed July 22
Landau, S.M., Lu, M., Joshi, A.D., Pontecorvo, M., Mintun, M.A., Trojanowski, J.Q., Comparing PET imaging and CSF measurements of Ab (2013) Ann Neurol, 74, pp. 826-836
Fagan, A.M., Mintun, M.A., Mach, R.H., Lee, S.Y., Dence, C.S., Shah, A.R., Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans (2006) Ann Neurol, 59, pp. 512-519
Morra, J.H., Tu, Z., Apostolova, L.G., Green, A.E., Avedissian, C., Madsen, S.K., Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls (2008) Neuroimage, 43, pp. 59-68
Fischl, B., Salat, D.H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain (2002) Neuron, 33, pp. 341-355
Wolz, R., Aljabar, P., Hajnal, J.V., Hammers, A., Rueckert, D., Alzheimer's disease neuroimaging initiative. LEAP: Learning embeddings for atlas propagation (2010) Neuroimage, 49, pp. 1316-1325
Chen, K., Ayutyanont, N., Langbaum, J.B., Fleisher, A.S., Reschke, C., Lee, W., Characterizing Alzheimer's disease using a hypometabolic convergence index (2011) Neuroimage, 56, pp. 52-60
Herholz, K., Salmon, E., Perani, D., Baron, J.C., Holthoff, V., Frolich, L., Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG-PET (2002) Neuroimage, 17, pp. 302-316
Frisoni, G.B., Bocchetta, M., Chetelat, G., Rabinovici, G.D., De Leon, M.J., Kaye, J., Imaging markers for Alzheimer disease: Which vs how (2013) Neurology, 81, pp. 487-500
Westman, E., Cavallin, L., Muehlboeck, J.S., Zhang, Y., Mecocci, P., Vellas, B., Sensitivity and specificity of medial temporal lobe visual ratings and multivariate regional MRI classification in Alzheimer's disease (2011) PLoS One, 6, p. e22506
Galluzzi, S., Geroldi, C., Ghidoni, R., Paghera, B., Amicucci, G., Bonetti, M., The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment (2010) J Neurol, 257, pp. 2004-2014
Le, C.D.G., Doust, J., Creasey, H., Brayne, C., Political drive to screen for pre-dementia: Not evidence based and ignores the harms of diagnosis (2013) BMJ, 347, p. f5125
Frisoni, G.B., Pievani, M., Testa, C., Sabattoli, F., Bresciani, L., Bonetti, M., The topography of grey matter involvement in early and late onset Alzheimer's disease (2007) Brain, 130, pp. 720-730
Bouwman, F.H., Schoonenboom, N.S., Verwey, N.A., Van Elk, E.J., Kok, A., Blankenstein, M.A., CSF biomarker levels in early and late onset Alzheimer's disease (2009) Neurobiol Aging, 30, pp. 1895-1901
Mulley, A.G., Trimble, C., Elwyn, G., Stop the silent misdiagnosis: Patients' preferences matter (2012) BMJ, 345, p. e6572
(2014) Neurostat, , www.rad.washington.edu/research/Research/groups/nbl/neurostat-3d-ssp, University of Washington. Accessed July 22
(2014) Statistical Parametric Mapping. Statistical Parametric Mapping, , www.fil.ion.ucl.ac.uk/spm, Available at:, Accessed July 22
Olsson, A., Vanderstichele, H., Andreasen, N., Meyer, G.D., Wallin, A., Holmberg, B., Simultaneous measurement of betaamyloid( 1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology (2005) Clin Chem, 51, pp. 336-345
